Decision Diagnostics (OTCMKTS:DECN - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Profitability This table compares Decision Diagnostics and 10x

Biotricity (OTCMKTS:BTCY - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Biotricity and 10x

PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m.

Torex Gold Resources Inc. (TXG:CA) Q4 2025 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.4 per share a year ago.

PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.

10x Genomics (NASDAQ: TXG - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current ratings

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.